Ribavirin approved with a big fat price
- PMID: 11365818
Ribavirin approved with a big fat price
Abstract
AIDS: Schering-Plough has received FDA approval to market a combination of Ribavirin and Interferon-Alpha for the treatment of hepatitis C. The approval has only been granted for patients who have relapsed after previously being treated by Interferon only. The approval was granted based on two clinical trials, and the manufacturer has announced positive results from another trial that has not yet been published. Schering-Plough has applied to the FDA for expanded approval to include patients who have not been previously treated. The company's prices for the combination drug are very high, and are estimated to be 265 percent higher than prices in Mexico.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical